<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216644</url>
  </required_header>
  <id_info>
    <org_study_id>FLOT4</org_study_id>
    <nct_id>NCT01216644</nct_id>
  </id_info>
  <brief_title>5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer</brief_title>
  <official_title>A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with locally advanced resectable adenocarcinoma of the stomach or the
      esophagogastreal junction without previous therapy will be treated with one of two
      chemotherapy combinations before and after surgery. One half of the patients gets
      5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT), the others Epirubicin,
      Cisplatin and 5-FU (ECF). Main objective of the study is median overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      714 Patients with locally advanced resectable (T2-4 and/or N+, M0) adenocarcinoma of the
      stomach or the esophagogastreal junction without previous therapy will be included in this
      study. After randomization patients receive perioperatively 4 cycles FLOT or 3 cycles ECF,
      followed by a restaging of the tumour status and surgery. Subsequently another 4 cycles of
      FLOT or 3 cycles ECF are applicated. Then a central validation of the pathological remission
      rate is scheduled. Primary endpoint is overall survival, secondary endpoints are disease free
      survival, perioperative morbidity and mortality, histopathologic regression rate and
      R0-resection rate.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>median overall survival</measure>
    <time_frame>2 years follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>histopathological regression rate</measure>
    <time_frame>6 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival (DFS)</measure>
    <time_frame>2 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation of pCR and DFS with survival</measure>
    <time_frame>2 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Morbidity and Mortality</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0-Resection rate</measure>
    <time_frame>2 months after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">716</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>FLOT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epirubicin 50 mg/m2, d1 Cisplatin 60 mg/m², d1 5-FU 200 mg/m², d1-d21 every 3 weeks (q3w) 3 cycles (9 weeks) pre-OP and 3 cycles (9 weeks) post-OP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>2600 mg/m²d1 i.v. every 2 weeks</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>200 mg/m², d1, i.v., every 2 weeks</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85 mg/m², d1, i.v., every 2 weeks</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>50mg/m2, d1, i.v., every 2 weeks</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>50 mg/m2, d1, i.v., every 3 weeks</description>
    <arm_group_label>ECF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>60 mg/m², d1, i.v., every 3 weeks</description>
    <arm_group_label>ECF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>200 mg/m², d1-d21, i.v., every 3 weeks</description>
    <arm_group_label>ECF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. locally advanced (&gt;T1) and/or nodal positive (N+) histologically proven adenocarcinoma
             of the esophagogastreal junction (AEG I-III) or the stomach without distant metastases
             (M0) and without infiltration of adjacent structures and organs

          2. no previous surgical resection

          3. no previous cytostatic chemotherapy

          4. Age &gt; 18 years (female and male)

          5. ECOG ≤ 2

          6. surgical resectability

          7. Exclusion of peritoneal carcinomatosis (if clinically suspected) via laparoscopy

          8. Leucocytes &gt; 3.000/µl

          9. Platelets &gt; 100.000/µl

         10. Serum creatinin ≤ 1.5x of normal value, or Creatinin-Clearance &gt; 50 ml/min

         11. written informed consent.

         12. Ejection fraction &gt; 50% in echocardiography before start of therapy

        Exclusion Criteria:

          1. distant metastases or infiltration of adjacent structures or organs and all primarily
             not resectable stages

          2. relapse

          3. Hypersensitivity against 5- Fluorouracil, Leucovorin, Oxaliplatin, Cisplatin.
             Epirubicin and Docetaxel

          4. Existence of contraindications against 5- Fluorouracil, Leucovorin, Oxaliplatin,
             Cisplatin, Epirubicin or Docetaxel

          5. Active CHD, Cardiomyopathy or cardiac insufficiency stage III-IV according to NYHA

          6. malignant secondary disease, dated back &lt; 5 years (exception: In-situ-carcinoma of the
             cervix uteri, adequately treated skin basal cell carcinoma)

          7. severe non-surgical accompanying disease or acute infection

          8. peripheral polyneuropathy &gt; NCI Grad II

          9. severe liver dysfunction (AST/ALT&gt;3,5xULN, AP&gt;6xULN, Bilirubin&gt;1,5xULN)

         10. chronic inflammable gastro-intestinal disease

         11. inclusion in another clinical trial

         12. pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah-Eddin Al-Batran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Clinical Cancer Research (IKF), UCT - University Cancer Center, Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Krankenhaus Nordwest</investigator_affiliation>
    <investigator_full_name>Prof. Dr. S.E. Al-Batran</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>perioperative</keyword>
  <keyword>FLOT</keyword>
  <keyword>ECF</keyword>
  <keyword>pathological complete remission</keyword>
  <keyword>locally advanced resectable adenocarcinoma of the esophagogastric juction or the stomach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

